Research programme: GPCR modulators - cancer therapies - Heptares Therapeutics

Drug Profile

Research programme: GPCR modulators - cancer therapies - Heptares Therapeutics

Alternative Names: Adenosine A2A modulators; CXCR-4 modulators

Latest Information Update: 25 May 2016

Price : $50

At a glance

  • Originator Heptares Therapeutics
  • Developer AstraZeneca; Heptares Therapeutics
  • Class Small molecules
  • Mechanism of Action Adenosine A2A receptor antagonists; Chemokine receptor antagonists; G protein-coupled receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 25 May 2016 Preclinical trials in Cancer in United Kingdom (PO) before May 2016
  • 23 Feb 2015 Heptares Therapeutics has been acquired by Sosei
  • 15 Dec 2014 Heptares Therapeutics has patent protection for StaR™ (stabilised receptor) technology platform in USA, Europe, China, Japan and Australia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top